Anthropic reports early drug development results with Claude across six partner organizations

What Anthropic published

Anthropic published on 27 October 2026 a report on drug development work with six partner organizations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. The report also covers Anthropic's own program through Mithril Medicine, a one-person company it acquired that works on treatments for two rare forms of muscular dystrophy. Anthropic says all of the work is at an early, mostly preclinical stage, and each case links to a technical report.

At Generate Biomedicines, six scientists used Claude Code to propose new designs for a genetic component used in CAR T-cell therapy. One design was about 70% shorter than the standard version. In lab tests, Anthropic reports that it let immune cells make roughly 10 times as many receptors, kill tumor cells more efficiently and stay active longer. At Divergence Labs, Claude turned the team's goals into a design plan and generated roughly 35,000 antibody designs in about a month for food allergy work. Early tests found three designs that bind IgE and 20 that can dislodge it from immune cells; three of those 20 performed better than the standard medication on that measure.

What the other partners reported

At BigHat Biosciences, Claude was connected to the company's lab data system and proposed changes to two antibody fragments. About 1,010 variants were made and tested over roughly 10 weeks. The best versions bound more than 10 times more tightly, one lead stayed in solution at a temperature 18 degrees Celsius higher, and another clumped more than 100 times more slowly. Claude also reanalyzed raw data after the team suspected the standard metrics were misleading.

At Enveda, Claude reviewed 1,061 pages of manufacturing and regulatory documentation. It caught all 11 issues that human reviewers had found and flagged seven more they had missed, and human review time fell by 89%, from over 25 hours to under three. Claude's first draft of one regulatory document took four hours, against about three months by hand; human review of a second draft found one minor error. Bristol Myers Squibb is using Claude to assess early-stage clinical trial plans and estimate their likelihood of success, with plans to expand the work in 2027. The Column Group is creating Pleiades, a company that will use Claude to run drug programs with a small team; its first Claude skill, for assessing drug targets, was evaluated on 45 target-disease pairs.

How to read these results

Every result is reported by Anthropic and the partner involved, and none has reached human trials. Several outcomes are conditional: Divergence still has to combine its two antibody arms into one drug, and Anthropic's own Mithril program is expected to be ready for human trials as soon as late 2028 only if its candidates hold up. The strongest numbers are the ones with a direct human comparison, such as the Enveda document review, and the weakest are the ones that depend on lab assays the report summarises rather than publishes. The technical reports linked from each case are the place to check methods.

What to watch next

Anthropic says it plans to expand its life sciences work substantially, extend Claude's role into clinical trials as programs advance, and partner with organizations already at the clinical stage. Researchers can apply through Claude Science, Claude credits for life scientists, the Life Sciences Verification Program, which offers more permissive safeguards to trusted organizations, and an open call for guest investigators. The next checkpoints are peer-reviewed publications of the preclinical data and the first investigational new drug filing from any of the programs. More science stories are listed under AI Research.

Questions people ask

Has any drug from Anthropic's program been tested in humans?

No. Anthropic says the work is at an early, mostly preclinical stage. It expects a drug from the Mithril program to be ready for human trials as soon as late 2028 if the candidates hold up.

Which companies worked with Anthropic on these results?

BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, plus Anthropic's own Mithril Medicine program.

Which Claude model produced the results?

The report refers to Claude, Claude Code and Claude Science and does not name specific model versions.

Sources

1. Early progress on accelerating drug development with Claude (Anthropic, 27 Oct 2026)